Supplementary Tables S1-S7 from Detection of Brain Cancer Using Genome-wide Cell-free DNA Fragmentomes
dataset
posted on 2025-08-04, 07:21 authored by Dimitrios Mathios, Noushin Niknafs, Akshaya V. Annapragada, Ernest J. Bobeff, Elaine J. Chiao, Kavya Boyapati, Keerti Boyapati, Sarah Short, Adrianna L. Bartolomucci, Stephen Cristiano, Shashikant Koul, Nicholas A. Vulpescu, Leonardo Ferreira, Jamie E. Medina, Daniel C. Bruhm, Vilmos Adleff, Małgorzata Podstawka, Patrycja Stanisławska, Chul-Kee Park, Judy Huang, Gary L. Gallia, Henry Brem, Debraj Mukherjee, Justin M. Caplan, Jon Weingart, Christopher M. Jackson, Michael Lim, Jillian Phallen, Robert B. Scharpf, Victor E. Velculescu<p>Supplementary Table S1. Clinical information, sequencing statistics, and ARTEMIS-DELFI scores for cfDNA analyses in Discovery cohort. Supplementary Table S2. Clinical information, sequencing statistics, and ARTEMIS-DELFI scores for cfDNA analyses in Validation cohort. Supplementary Table S3. Summary of mutations detected by plasma-based targeted sequencing panel. Supplementary Table S4. Correlation of TF expression between GBM and other tumor types. Supplementary Table S5. Summary of complete blood count for patients with gliomas or non-neoplastic neurological conditions. Supplementary Table S6. Summary of ChIP-Seq peaks used in DECIFER analysis. Supplementary Table S7. Correlation of TFBS relative coverage differences with expression differences between tumor/cell types and whole blood.</p>
Funding
Dr. Miriam and Sheldon G. Adelson Medical Research Foundation (AMRF)
Gray Foundation
Commonwealth Foundation for Cancer Research Foundation
Mark Foundation For Cancer Research (The Mark Foundation for Cancer Research)
Conquer Cancer Foundation (CCF)
Cole Foundation (CF)
Center for Cancer Research (CCR)
American Association for Cancer Research (AACR)
History
Related Materials
- 1.
